WORCESTER, Mass., Aug. 15, 2011 (GLOBE NEWSWIRE) -- RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, today reported its financial results for the quarter ended June 30, 2011.
